Novo Integrated Sciences Stock (NVOS): Price, Financials & Risks

If you’ve typed “novo integrated sciences stock” into a search bar, you’ve probably already seen the headline numbers: a share price measured in fractions of a cent, wild daily swings, and a company that got kicked off Nasdaq. None of that tells you much on its own. This piece walks through what Novo Integrated Sciences actually does, how the stock got to where it is, and what the financials say before you decide anything.

This article is for information only. It isn’t investment advice, and NVOS is a thinly traded micro-cap stock, so treat any numbers here as a starting point for your own research, not a signal to buy or sell.

What Is Novo Integrated Sciences?

Novo Integrated Sciences, Inc. trades under the ticker NVOS. The company didn’t start life in healthcare at all. It was originally incorporated as Turbine Truck Engines, Inc., and only took on its current name and business focus in 2017 after a pivot into medical services. Today it’s headquartered in Bellevue, Washington, and run by CEO Robert Mattacchione, but the actual operations sit mostly in Canada through a network of wholly owned subsidiaries, click here,

The business splits into two segments:

• Healthcare Services — physiotherapy, chiropractic care, occupational therapy, massage therapy, acupuncture, chiropody, concussion management, and rehabilitation for stroke or traumatic brain injury. Much of this runs through community clinics, retirement homes, and long-term care facilities across Canada, plus home-based and eldercare programs.
• Product Sales — remote patient monitoring, telehealth platforms, and personalized wellness products sold through Novo’s subsidiaries.

For a broader rundown of how those pieces fit together, our comprehensive overview of Novo Integrated Sciences goes deeper into the corporate structure.

From Nasdaq to OTC Markets

This is the part a lot of new investors miss. NVOS used to trade on the Nasdaq Capital Market, but it fell out of compliance with Nasdaq’s minimum bid price rule (shares had to stay above $1.00) and never regained it. The company received a delisting determination letter in early November 2024, and trading moved to the OTC Markets under the same ticker, NVOS, shortly after.

This wasn’t the company’s first brush with the $1.00 threshold, either. Novo carried out a 1-for-10 reverse split back in February 2021 specifically to qualify for its original Nasdaq uplisting, and did another 1-for-10 reverse split in November 2023 to try to hang onto that listing. Neither fix stuck long-term, and the stock is now an OTC name, which generally means looser reporting requirements, thinner trading volume, and wider bid-ask spreads than an exchange-listed stock.

NVOS Stock Price and Key Numbers

Numbers on Novo Integrated Sciences stock vary a bit depending on which data provider you check, mostly because of differences in how they count shares outstanding after two reverse splits. Here’s a snapshot pulled from recent public data:

The takeaway from that table: revenue is real and has grown slightly year over year, but the company is spending far more than it brings in, and it’s doing so with very little cash cushion. For a closer look at how the price itself has swung and what’s been driving those moves, see our piece on navigating the volatility in Novo Integrated Sciences stock.

Why the Stock Keeps Showing Up on Watchlists

A company running $16 million net losses on $13 million in revenue doesn’t usually attract much retail attention. NVOS does, for a few reasons:

Rock-bottom share price: When a stock trades for fractions of a cent, traders can buy huge share counts with a small amount of money, which appeals to people chasing a fast percentage move rather than steady, long-term growth.

A real, understandable business: Physiotherapy clinics and rehab services aren’t hard to explain, and healthcare is a sector most people assume is a safe bet, even when a specific company inside it isn’t profitable.

News-driven spikes: Financing announcements, letters of credit being monetized, leadership updates, or partnership news have a track record of producing short bursts of buying, which keeps the ticker active on stock-alert sites and forums. Our page on NVOS sentiment over on Stocktwits tracks how retail traders are reacting to that kind of news in something closer to real time.

None of that changes the underlying math. It just explains why the stock stays on people’s radar despite the numbers above.

Risks Worth Weighing

Dilution: Novo has leaned on promissory notes and standby letter of credit arrangements to raise cash. These deals often come with terms that increase the total share count over time, which can shrink the value of shares an existing holder already owns, even if nothing else about the business changes.

Liquidity: Thin trading volume on an OTC stock means the price you actually get filled at can differ meaningfully from the last quoted price, especially on larger orders.

Going-concern pressure: Sustained losses and negative operating cash flow mean Novo depends on continued outside financing. There’s no guarantee that financing stays available on reasonable terms.

Volatility: A beta above 4 means this stock can move multiples of what the broader market does, in either direction, on any given day.

Is Novo Integrated Sciences Stock a Buy?

That’s not a question anyone can answer for you from a blog post, and honestly, be skeptical of anyone who claims they can. What’s true is that Novo is an operating business with actual clinics, staff, and revenue, not a shell company. 

What’s also true is that it’s a going concern working through heavy losses, a thin cash position, and a stock chart that’s scared off plenty of longer-term holders already. If you’re seriously considering a position, read the company’s actual SEC filings and OTC disclosures rather than relying on price charts or forum chatter, and size any trade according to how much you can afford to lose on a speculative micro-cap.

FAQs

What does NVOS stand for? 

NVOS is the OTC Markets ticker symbol for Novo Integrated Sciences, Inc., a healthcare services and wellness products holding company based in Bellevue, Washington.

Is Novo Integrated Sciences stock still on Nasdaq? 

No. The company was delisted from the Nasdaq Capital Market in November 2024 after failing to maintain the required $1.00 minimum bid price, and it now trades on OTC Markets under the same ticker.

Has NVOS done a reverse stock split? 

Yes, twice. Novo carried out 1-for-10 reverse splits in February 2021 and again in November 2023, both aimed at meeting Nasdaq’s minimum price rule.

Is Novo Integrated Sciences profitable? 

No. The company reported a trailing twelve-month net loss of roughly $16.2 million against revenue of about $13.3 million, a net margin around -122%.

Why has the stock fallen so much? 

The decline tracks a mix of ongoing net losses, negative operating cash flow, share dilution from financing deals, and the general risk profile of a thinly traded, sub-penny OTC stock once early speculative interest cools off.

Where can I follow NVOS news and price updates? 

Standard brokerage platforms and financial data sites carry real-time OTC quotes. For a rundown on the company itself and how we cover it, check our About Us page, or reach out through Contact Us with specific questions.

Conclusion

Novo Integrated Sciences stock sits in a category that’s easy to describe and hard to predict: a real healthcare business with clinics and paying customers, wrapped around a balance sheet that’s still deep in the red. 

The Nasdaq delisting, the two reverse splits, and the sub-penny share price all point to the same underlying story: a company that’s struggled to turn healthcare revenue into anything close to profit. That doesn’t make NVOS uninvestable, but it does make it a stock that rewards actually reading the filings over watching the chart. Do your homework, understand the dilution and liquidity risks above, and only put in what you’re prepared to lose.